跳至主要内容
临床试验/IRCT2016110630726N1
IRCT2016110630726N1招募中1 期

Evaluation TH1 and TH17 immune response mechanisms involved in the pathogenesis of Crohn's disease, following intravenous injection of autologous mesenchymal stem cells in refractory Crohn's disease patients.

Vice Chancellor for Research and Technology University, Mashhad University of Medical Sciences0 个研究点目标入组 17 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方
入组人数
17

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Patients at least 18 years of age; Crohn’s Disease Activity Index (CDAI) score between 220 and 450; Colonoscopy performe at baseline to confirm disease activity; Patients have to be refractory to the standard treatment options for Crohn’s disease; such as: steroids, immunosuppressive agents (eg, azathioprine, 6-mercaptopurine or methotrexate) or anti-TNF therapy. Exclusion criteria:History of malignancy during the course of treatment or during the last 5 years.

排除标准

  • 未提供

研究者

发起方
Vice Chancellor for Research and Technology University, Mashhad University of Medical Sciences

相似试验

Applying of stem cells to treat crohn's disease | 临床试验